MorphoSys AG — Regulatory Filings 2001

Sep 17, 2001

News Details

Ad-hoc | 17 September 2001 07:44

MorphoSys AG english

Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– MorphoSys Expands Target Discovery Capability in Oridis Biomed Collaboration Preferred Access to one of World’s Largest Human tissue banks Martinsried/Munich, September 17, 2001 – MorphoSys AG (Neuer Markt: MOR), the German biotechnology company, announced today an Agreement with Oridis Biomed Forschungs- und Entwicklungs GmbH, Graz, Austria, that will provide MorphoSys with preferred access to one of the worlds largest human tissue banks. The goal of the collaboration is the characterization and validation of new therapeutic targets. MorphoSys will apply its HuCAL technology to make antibodies to candidate targets, which Oridis Biomed will use to carry out high throughput protein expression analysis on a range of human tissues. Oridis Biomed receives a license to the MorphoSys HuCAL technology, and will have access to certain antibodies from MorphoSys. MorphoSys receives a first right of negotiation to all antibody products resulting from the collaboration. No financial terms were disclosed. The tissue collection resides at the Institute of Pathology, University of Graz, Austria. With 1.4 million paraffin-embedded and 18,000 frozen human tissue samples, the collection is one of the largest in the world. Under an agreement with the Institute, Oridis Biomed has exclusive rights to exploit the collection for commercial purposes. The collection contains a large number of annotated healthy and diseased tissues, and is expected to be exploited by Oridis Biomed to map and quantify the occurrence of potential therapeutic targets. end of ad-hoc-announcement (c)DGAP 17.09.2001 ——————————————————————————– WKN: 663200; Index: Nemax 50 Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 170744 Sep 01